PROPATEN heparin-bonded vascular graft for peripheral arterial disease

NICE has developed a medtech innovation briefing (MIB) on the PROPATEN heparin-bonded vascular graft for peripheral arterial disease.

The Gore PROPATEN heparin-bonded vascular graft is a synthetic graft used to treat peripheral arterial disease by bypassing damaged blood vessels. The graft is made from expanded polytetrafluoroethylene that has a layer of heparin anticoagulant bonded to its inner surface, which is designed to reduce graft occlusion. Relevant evidence was limited and consisted of 1 randomised controlled trial and 5 cohort studies, with either artificial graft or autologous vein graft comparators. The reports indicate that the PROPATEN graft is either equivalent or inferior to autologous vein grafts in maintaining patency (that is, remaining open and functional over time). In scenarios where vein grafts could not be used, PROPATEN performed at least as well or better than other types of artificial graft. The manufacturer declined to provide the cost of a PROPATEN graft. Based on similar products, and expert advice, the likely cost of a PROPATEN graft is estimated to be between £600 and £1000, excluding VAT.  

Medtech innovation briefings provide a description of the medical technology, including its likely place in therapy, the costs of using the technology and a critical review of the strengths and weaknesses of the relevant published evidence.

Their purpose is to provide objective information on device and diagnostic technologies to aid local decision-making by clinicians, managers and procurement professionals. By making this information available, NICE helps to avoid the need for NHS organisations to produce similar information for local use.

Medtech innovation briefings are not NICE guidance. They differ in format, contain no judgement on the value of the technology and do not constitute a guidance recommendation.

MIBs are commissioned by NHS England and produced in support of the NHS 5 Year Forward View, specifically as one of a number of steps which will accelerate innovation in new treatments and diagnostics.